Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region

NCT00230191 is registered in ClinicalTrials.gov with RxKinetix as lead sponsor.

NCT NCT00230191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00230191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region
Lead sponsor
RxKinetix
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
December 31, 2005
Enrollment
110
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, mouth diseases, mouth ulcers, oral mucositis